Cambridge, UK, 07 July 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the introduction of its stably expressing Cas9 and dCas9-VPR cell lines to help accelerate gene knockout and gene activation experiments, respectively.
News
AMSBIO has introduced StemFit® for Differentiation - a new chemically defined and animal component-free formulation that enables unmatched differentiation of human Induced Pluripotent Stem (hiPS) and Embryonic Stem (hES) cells.
The unique chemically defined composition of StemFit® for Differentiation minimizes lot-to-lot variation, enabling highly consistent cell differentiation. Free of animal- and human-derived components, StemFit® for Differentiation can be used to eliminate the risk of immunogenic contamination.
- Funds to be used to drive transformative strategic growth initiatives
Tokyo, Japan and London, UK, 16 July 2020 – Sosei Group Corporation (“the Company”; TSE: 4565) today announces the successful completion of an International Offering of new shares and euro-yen denominated convertible bonds due 2025 that has raised a total of approximately $200 million. Further details of the International Offering can be found in the Company announcements made on 30 June 2020.
Industry programme created to solve the business challenges that keep life sciences leaders and innovators up at night.
Deloitte has launched the Life Sciences Catalyst in Cambridge, a collaborative platform enabling organisations in the biotech, medtech, pharmaceutical and technology sectors, as well as prospective investors, to come together to tackle the biggest challenges facing their industries.
The research use only kit can be used as a simple alternative to RT-qPCR for SARS-CoV-2 analysis
IPSWICH, MA (July 6, 2020): New England Biolabs® (NEB®) today announced the launch of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, a Research Use Only (RUO) product that can be used for the detection of novel coronavirus, SARS-CoV-2 RNA. The kit serves as a simple alternative to RT-qPCR and enables visual detection of amplification of SARS-CoV-2 nucleic acid in just 30 minutes.
- Muscular Dystrophy UK (MDUK) supports high quality research that drives rapid access to emerging therapies for people with muscle-wasting conditions.
- Facioscapulohumeral muscular dystrophy (FSHD) is a rare muscle-wasting disease affecting an estimated 3-5 in every 100,000 people worldwide.
- This partnership will combine Healx’s AI-driven drug discovery expertise with MDUK’s patient insight to identify novel therapeutic options for FSHD.
The BioChemGRAPH collaboration brings together key chemical and biochemical datasets, to give researchers deeper insights than ever before.
A collaboration announced today will see the integration of key structural, functional, and biochemical data across both small molecules and macromolecules. This will allow researchers to quickly access relevant information from trusted but disparate datasets, advancing work in fields such as target validation, drug development, drug repurposing and cross-reactivity.
The Aim
Cambridge, United Kingdom – 15 July 2020 - Congenica, a digital health company enabling rapid analysis of complex genomic data, has launched an update for its clinical decision support platform that will provide automated classification, evidence and reporting of recurrent ‘known’ variants that customers observe in their rare disease cases, significantly saving time while maximizing diagnostic yield and laboratory throughput.
Eastern AHSN (Academic Health Science Network) has published its latest impact review (for the period April 2019 to 31 March 2020) highlighting how they turned great ideas into positive health impact last year, told largely in the words of the people they worked with.
San Diego, California and Saffron Walden, UK, 14th July 2020 / Sciad Newswire / Invivoscribe, Inc., an industry pioneer and global leader in the field of precision diagnostics announces the launch of a fully integrated drug development engine. This new engine will combine with its in-house expertise in diagnostics development and worldwide access to patients and clinical testing capabilities to accelerate drug development.